Physicians

Director of the AIDS Research and Treatment Center
Associate Director of Research

Departments / Divisions

• Medicine / Medicine-Infectious Diseases
• School of Nursing
• DGHI-Parent / DGHI-Admin

Address
DUMC 3238
Durham, NC 27710

Appointment Telephone
919-668-7630

Office Telephone
919-681-8043

Fax Telephone
919-681-7748

Training

• MD, University of Virginia School of Medicine, 1981

Residency

• Infectious Diseases, Duke University Medical Center, 1982-1984, 1985-1987

Clinical Interests
General infectious diseases, human immune deficiencies, HIV, AIDS

Research Interests
My clinical investigation is focused on the pathogenesis and treatment of HIV infection and its complicastions, especially in resource-limited settings.

Key Words: HIV infection, AIDS, treatment strategies, treatment failure, co-infections, resource-limited settings

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Argos Therapeutics, Inc.
• Merck & Co. USA (not assoc'd with Merck KGaA)

Representative Publications
Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. Journal of Infectious Diseases. 177:231-234, 1997. (1997)

Bartlett JA, Hullette C. Central nervous system pneumocysostis in the acquired immune deficiency syndrome. Clinical Infectious Diseases. 25:82-85, 1997. (1997)

Ferrari G, Berend C, Ottinger J, Dodge R,Bartlett J, Toso J, Moody D, Tartaglia J, Cox W, Paoletti E, Weinhold K. Replication -defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiemcy virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood, (90) 6; 2406-2416, 1997. (1997)

Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA and Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. Journal of Immune Deficiency Syndromes and Human Retrovirology. 16:100-107, 1997. (1997)

Staszewski S, Hill AM, Bartlett JA, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 11:477-483, 1997. (1997)

Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. Submitted to Journal of Infectious Diseases.

Bartlett JA, Wasserman S, Hicks C, Dodge R, Weinhold K, Tacket C, Ketter N, Wittek A, Palker T, Haynes BF and the DATRI 010 Study Group. Safety and immunogenicity of C4V3 polyvalent synthetic peptides in HIV-infected HLA B7 positive subjects with CD4 cells > 500/mm3. Submitted to Journal of Infectious Diseases.